Stray Dog

Kentucky rejects federal peptide easing, a risk for HIMS

  • Bad news: Kentucky's pharmacy board gave no exemption to the 6 peptides eased by HHS on 28 Oct, and told pharmacies to stop shipping in at once.
  • Bad news: A national launch of BPC-157 and TB-500 now looks like a state-by-state patchwork.
  • Bad news: The American Medical Association called on HHS to withdraw the policy, which shows how shaky the federal footing is.
Read the full notes

Kentucky becomes the first state to oppose the federal easing on peptides, so a national launch of BPC-157 and TB-500 would turn into a state-by-state patchwork. The footing of federal enforcement discretion is shaky, and the American Medical Association has called for the policy to be withdrawn.

Key evidence

  • On 18 Nov the Kentucky Board of Pharmacy voted to give no exemption to the 6 peptides (BPC-157, TB-500, Epitalon, Semax, KPV, MOTS-c) on which HHS eased enforcement on 28 Oct.
  • On 19 Nov Kentucky sent a compliance notice to every pharmacy licensed to deliver into the state, including out-of-state ones: stop compounding, dispensing and shipping in immediately, with no grace period. Violators risk licence revocation or fines.
  • The board's reasoning: state rules require compounding ingredients to have an official pharmacopoeia standard, come from an FDA-approved drug, or be on the FDA ingredient list, and none of the 6 qualifies. Federal enforcement discretion only means no prosecution. It does not make them legal and cannot override state law.
  • Utah says it will follow federal policy. Arizona, Massachusetts and Illinois are still deciding.
  • On 18 Nov the American Medical Association publicly called on HHS to withdraw the policy: patients should not be made guinea pigs for unapproved drugs.
  • The 5 existing HIMS Peptides+ products (sermorelin, NAD+, glutathione, B12, L-carnitine) are not among the 6.
Show 4 more
  • Kentucky has about 1.3% of the US population, so the direct short-term impact is small.
  • The real impact falls on the most anticipated next batch, BPC-157 and TB-500. The expectation was a national launch once HHS gave the go-ahead, but it is now a state-by-state patchwork.
  • The AMA statement, state-level opposition and last week's questioning by STAT and other media show that the footing of temporary federal enforcement discretion is shaky: the policy can be withdrawn and did not go through formal rulemaking.
  • No new SEC EDGAR filings since 19 Nov.

Catalysts to watch

  • Decisions by pharmacy boards in states such as Arizona, Massachusetts and Illinois
  • Whether HIMS publishes a list of states where BPC-157 and TB-500 are live
  • Whether HHS withdraws the 28 Oct policy or moves it into formal rulemaking

Risks

  • The scope and speed of a national BPC-157 and TB-500 launch will both have to be cut back
  • Every state pharmacy board could set up its own barriers, creating a state-by-state patchwork
  • The footing of temporary federal enforcement discretion is shaky and the policy can be withdrawn
  • The AMA's public opposition puts the policy's legitimacy in question
  • State law outranks federal enforcement discretion, so HIMS, as an out-of-state pharmacy, must comply state by state

Sources 5

  1. Peptide Daily, 20 Nov: key points of the board's compliance notice
  2. PepNews
  3. TheFly/Investing.com, 20 Nov
  4. American Medical Association press release, 18 Nov
  5. Beckers